Roshdy E, Rajaratnam V, Maitra S, Sabry M, Allah AS, Al-Hendy A
BPC-157 is a pentadecapeptide (15 amino acids) derived from a naturally occurring protective protein in the gastric mucosa
For example, pharmaceuticals such as ETX001 ( ACT or F ACT (Namkung et al., 2011) which would increase the activity of TMEM16A, subsequently increasing chloride and bicarbonate transport to propel water into mucus, or decrease the activity of ENaC, reducing sodium transport intracellularly and increasing water retained in mucus, could be very beneficial but are still far from public use (Livraghi-Butrico et al., 2013
Bhatt, D
The figure 25.3 % surpasses: Tirzepatide SURMOUNT-1: 22.5 % Semaglutide STEP-1: 14.9 % Retatrutide Phase 2: 24.2 % (comparable, but Phase 3 results for Retatrutide are still lacking) It raises the question whether CagriSema will be the first molecule with an effect truly comparable to bariatric surgery (typically 2530 % reduction)
